Drug Trial Radar · NCT07920939
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of SHR-3167 versus Insulin glargine in insulin-naive type 2 diabetes inadequately controlled on non-insulin anti-diabetic drugs. The hypothesis is that SHR-3167 is non-inferior to insulin glargine in the change of HbA1c from baseline after 26 weeks of treatment.
Conditions
- Type 2 Diabetes
Interventions
SHR-3167 InjectionDrug
SHR-3167 Injection
Insulin glargine (IGlar)Drug
Insulin glargine (IGlar)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c from baseline to week 26 (non-inferiority test)Time frame: baseline to week 26
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.